



TITLE: Oral Lidocaine for Reflux or Mucositis: Clinical Evidence and Guidelines

DATE: 25 October 2013

RESEARCH QUESTIONS

1. What is the comparative clinical evidence regarding oral lidocaine viscous 2% in combination with antacid versus antacid alone for the treatment of adults with (gastrointestinal reflux disease) GERD?
2. What is the comparative clinical evidence regarding treatments incorporating oral lidocaine viscous 2% versus non-lidocaine treatments for adults or children with mucositis?
3. What are the evidence based guidelines for the treatment of GERD or mucositis?

KEY MESSAGE

Two evidence-based guidelines were identified regarding oral lidocaine viscous 2% for mucositis. No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, or evidence-based guidelines were identified regarding oral lidocaine viscous 2% for GERD.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2010, Issue 10), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit retrieval by publication type for questions 1 and 2. A guideline filter was used to limit retrieval for question 3. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2003 and October 21, 2013. Internet links were provided, where available.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. **This report may be used for the purposes of research or private study only.** It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

Two evidence-based guidelines were identified regarding oral lidocaine viscous 2% for mucositis. No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, or evidence-based guidelines were identified regarding oral lidocaine viscous 2% for GERD. Additional references of potential interest are provided in the appendix.

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

1. Summary of 2004 MASCC* guidelines for the treatment of oral and GI mucositis [Internet]. Franklin (TN): Healthways; 2010. [cited 2013 Oct 23]. Available from: https://host1.medcohealth.com/art/corporate/pdf/Oral_Mucositis_Care_Guide.pdf
See: Foundation Level Care, page 4
2. Broadfield L, Hamilton J. Best practice guidelines for the management of oral complications from cancer therapy [Internet]. Halifax: Cancer Care Nova Scotia; 2006. [cited 2013 Oct 23]. Available from: http://www.cancercare.ns.ca/site-cc/media/cancercare/Oral_Care_CV_FINAL.pdf

PREPARED BY:

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439

www.cadth.ca

APPENDIX – FURTHER INFORMATION:

Qualitative Studies

3. Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. *J Oncol Pharm Pract.* 2005 Dec;11(4):139-43.
[PubMed: PM16595065](#)

Guidelines – methodology not specified

4. Mucositis in adults with cancer: screening and assessment [Internet]. In: CCO toolbox: symptom management tools. Toronto: Cancer Care Ontario; 2012 Jul [cited 2013 Oct 23]. Access document from: <https://www.cancercare.on.ca/toolbox/symptools/>.
Link to pdf under: Symptom Management Guides > Oral care > Mucositis algorithm
See: General Oral Care, page 2

Additional References

5. Treister NS. Chemotherapy-induced oral mucositis treatment & management [Internet]. New York: Medscape; 2013 Apr 23. [cited 2013 Oct 23]. Available from: <http://emedicine.medscape.com/article/1079570-treatment>
6. Kintzel PE. Oral mucositis in cancer patients. *Pharm Practice News Spec Ed* [Internet]. 2011 [cited 2013 Oct 23];87-93. Available from: http://www.pharmacypracticenews.com/download/Oral_mucositis_ppnse11_WM.pdf
7. Use of lidocaine in the GI cocktail for the treatment of dyspepsia. 2006 Nov 1 [cited 2013 Oct 23]. In: BestBETS [Internet]. Manchester (UK):1996 - . Available from: <http://www.bestbets.org/bets/bet.php?id=01262>
8. Crawley MM. Current trends in managing oral mucositis. *Clin J Oncol Nurs* [Internet]. 2005 Oct [cited 2013 Oct 23];9(5). Available from: <https://hci-portal.hci.utah.edu/sites/hci-nursing/bmt/Other%20Articles/Oral%20mucositis.pdf>